Last reviewed · How we verify
Tifcemalimab injection
Tifcemalimab injection is a monoclonal antibody that targets the PD-1 receptor.
Tifcemalimab injection is a monoclonal antibody that targets the PD-1 receptor. Used for Non-small cell lung cancer, Melanoma.
At a glance
| Generic name | Tifcemalimab injection |
|---|---|
| Sponsor | Shanghai Junshi Bioscience Co., Ltd. |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By binding to PD-1, tifcemalimab injection blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, which are expressed on tumor cells and tumor-associated immune cells. This blockade prevents the inhibition of T-cell activation and proliferation, leading to enhanced anti-tumor immune responses.
Approved indications
- Non-small cell lung cancer
- Melanoma
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Rash
- Pruritus
Key clinical trials
- Low-dose Radiotherapy Combined with Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC (PHASE1)
- Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tifcemalimab injection CI brief — competitive landscape report
- Tifcemalimab injection updates RSS · CI watch RSS
- Shanghai Junshi Bioscience Co., Ltd. portfolio CI